Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PXLW +12.4%, (sees Q4 revs at high end of guidance, expects to report GAAP profitability ) CUDA +8.5%, MDRX +6.7%, (ticking higher; reaffirms Q4 guidance and provides initial outlook for 2017 ), ZBH +3.8%, CMG +2.5%, EXPR +1.8%, OFIX +1.8%, TACO +1.7%, (preannounces Q4 sales with comps +5.5%, just above estimates), VOXX +0.9%, ZLTQ +0.7%, (discloses commercial leadership transition, provides prelim Q4 results, FY17 guidance),
M&A news:
- VRX +11.7% (divests its CeraVe, AcneFree and AMBI Skincare brands To L'Oreal (LRLCY) for $1.3 bln; also to divest Dendreon for $819.9 mln; )
Select metals/mining stocks trading higher:
- RIO +5.1%, VALE +4.7%, BBL +4.7%, CLF +4.6%, MT +4.4%, FCX +4.1%, X +2.9%, AKS +2.3%
Other news:
- NGNVC +44.5% (continued strength; extending late surge higher yesterday), XGTI +20% (regains full compliance with all listing requirements of the Nasdaq), ILMN +14% (confirms the introduction the NovaSeq Series, a new and scalable sequencing architecture expected one day to enable a $100 genome; Illumina and Bio-Rad Laboratories launch of the Illumina Bio-Rad Single-Cell Sequencing Solution), ARRY +8.1% (still checking), PTX +6.3% (continued strength), SSI +5.7% (modestly rebounding), KITE +3.5% (Kite Pharma enters into a strategic partnership with Daiichi Sankyo Co for axicabtagene ciloleucel) PSTI +3.4% (announced that its Phase III study of its PLX-PAD cells in the treatment of critical limb ischemia was cleared by the FDA; expects to begin enrolling patients in its Phase III study in both the U.S. and Europe during 1H17), BIO +3% (Illumina and Bio-Rad Laboratories launch of the Illumina Bio-Rad Single-Cell Sequencing Solution), PBR+2.8% (prices $4 bln in Global Notes), CNDT +2.4% (higher in after hours after Carl Icahn affirmed 9.77% active stake in the Xerox (XRX) spin-off ), ZIOP +2.4% (ZIOPHARM & Intrexon (XON) announce cooperative research and development agreement with the National Cancer Institute utilizing sleeping beauty system to generate T cells targeting neoantigens),FEYE +1.7% (in sympathy with CUDA), CYBR +1.1% (in sympathy with CUDA),
Analyst comments:
- TIME +2.7% (upgraded to Outperform from Market Perform at Wells Fargo), ETFC +1.8% (upgraded to Buy from Neutral at Goldman ), VOD +1.7% (upgraded to Buy from Neutral at Goldman ), XRX +1.6% (upgraded to Buy from Neutral at Goldman ), BIDU +1% (upgraded to Buy from Hold at Stifel)